Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)Skin and Connective Tissue Diseases, autoimmune disease, immune system disorder, pemphigus, pemphigus vulgaris, skin disorder, vesiculobullous skin diseaseRecruitingPhase 1 / Phase 22026-05-29NCT04422912

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Cabaletta Bio5

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Brigham and Women's HospitalBostonUnited States511
Columbia UniversityNew YorkUnited States154
MD Anderson Texas Medical CenterHoustonUnited States1
Mount Sinai - Icahn School of MedicineNew YorkUnited States1
Northwestern UniversityChicagoUnited States727
Stanford University, Dept. of DermatologyRedwood CityUnited States1
UC Davis, Dept. of DermatologySacramentoUnited States1
University of IowaIowa CityUnited States284
University of North Carolina, Department of DermatologyChapel HillUnited States1
University of PennsylvaniaPhiladelphiaUnited States507
University of WashingtonSeattleUnited States36
UT Southwestern Medical Center, Dept. of DermatologyDallasUnited States1
Yale UniversityNew HavenUnited States352